Artem Oganesyan: Clonal Hematopoiesis and HCT Survivors
Artem Oganesyan, Resident Physician at Jefferson Abington Hospital, shared a post on LinkedIn about a paper he co-authored with colleagues, published in JNCI:
“In our recent analysis, survivors of autologous hematopoietic stem cell transplantation (HCT) with clonal hematopoiesis had a higher risk of subsequent development of non-myeloid malignancies and worse survival outcomes.
These findings advance our knowledge base regarding the development of secondary malignancies and clonal hematopoiesis in general. Clonal hematopoiesis may soon become a biomarker for risk stratification among HCT survivors.
Special thanks to Dr. Saro Armenian for leading this amazing project.”
Title: Clonal hematopoiesis and risk of nonmyeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantation
Authors: Michael Jefford, Julia Lai-Kwon, Ben Li, Wafik, Razelle Kurzrock, Alisa Coker, Diane Moran, Jill Barnholtz-Sloan, David Fajgenbaum, Lee Kiefer, Christopher Fletcher, Nils Eckardt, Christos Tsagkaris, Victoria Wolodzko Smart, Mark Lawler, Michelle Kirschner, Rebecca Bekker, William Breitbart, Grant Williams, Rodriguez-Rodriguez, Kira Young, Terri Armstrong
You can read the Full Article on JNCI: Journal of the National Cancer Institute.
More posts featuring Artem Oganesyan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023